Locations:
SearchAdvertisement
This op-ed offers a Cleveland Clinic expert's view
Most physicians and medical professionals understand that the COVID-19 vaccines, especially the mRNA vaccines, are safe, effective and the best way out of this pandemic. The general public, however, is inundated with misinformation and may lack the scientific literacy necessary to dispel circulating myths. Many physicians and scientists are speaking out, offering their knowledge and perspective to a public that is both ready to end the pandemic and confused about vaccine safety and efficacy.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Suneel Kamath, MD, staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center, offers his expertise to the public in a recent article in U.S. News & World Report. Dr. Kamath places the vaccines in the context of other drug studies for patients:
The concerns about theoretical long-term side effects of the COVID-19 vaccine are valid, but it’s important to contextualize them. The Pfizer vaccine has been studied in nearly 44,000 people, and the Moderna vaccine in 30,000 people, without any meaningful side effects or concerns for long-term issues. In comparison, most studies of the newest immunotherapy and personalized cancer drugs have less than 2,000 patients with minimal long-term safety data. Many people take supplements like cannabis oil or mushroom extracts without any evidence that these are safe long term. With vaccine studies this large and ongoing, there is no reason to scrutinize them any more than a new cancer drug or supplement.
Read the full article here, and consider sharing with patients who are hesitant to get vaccinated.
Advertisement
Advertisement
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Real-world results reporting aims to make treatments safer and more effective
Ongoing clinical validation in diverse populations refine breast cancer risk substratification
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel